Get a deeper insight into the potential performance of Viatris (VTRS) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Get a deeper insight into the potential performance of Maximus (MMS) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for PENN Entertainment (PENN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.

Beyond analysts' top-and-bottom-line estimates for TDS (TDS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.

Besides Wall Street's top-and-bottom-line estimates for Acushnet (GOLF), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.

Get a deeper insight into the potential performance of American Healthcare REIT (AHR) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Beyond analysts' top-and-bottom-line estimates for Haemonetics (HAE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.

Evaluate the expected performance of Consolidated Water (CWCO) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Get a deeper insight into the potential performance of Plug Power (PLUG) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Evaluate the expected performance of Mercury Systems (MRCY) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Beyond analysts' top-and-bottom-line estimates for UWM (UWMC), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.

Besides Wall Street's top-and-bottom-line estimates for U.S. Cellular (USM), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.

Armada Hoffler is executing a disciplined capital allocation strategy focused on deleveraging, refinancing, and balance sheet optimization. Management is actively improving debt quality by replacing short-term, high-cost loans with longer-term, fixed-rate financing to support its pursuit of an investment grade rating. The portfolio is strengthening through stabilized deliveries and above-schedule lease-up at Allied, supporting normalized FFO growth.

Shares of Costco Wholesale Corporation ( NASDAQ: COST ) lost 3.87% over the past month after losing 6.33% the month prior.

Investors need to pay close attention to ROST stock based on the movements in the options market lately.

Novavax (NVAX) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of a loss of $0.07 per share. This compares to earnings of $0.99 per share a year ago.

Southwest Gas (SWX) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.31 per share a year ago.

Avnet (AVT) came out with quarterly earnings of $0.81 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $1.22 per share a year ago.

NEW YORK , Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Anika Therapeutics, Inc. ("Anika" or the "Company") (NASDAQ: ANIK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Lantheus remains a highly profitable company with a dominant market share, an exceptionally strong balance sheet with nearly $1 billion in cash, and robust free cash flow. The stock's decline was driven by a slowdown in growth for key products, a surprise business divestiture, a pipeline failure, and a lowered full-year 2025 guidance. Management is actively repositioning the company away from legacy products and into high-growth oncology and neurology segments through strategic acquisitions and a pipeline of new products expected in 2026.